読み込み中
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
前日終値
$23.81
+$1.24 · +5.49%
日中の時刻はETです。市場データは遅延する場合があります。
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
日中レンジ
現在 $23.81
52週レンジ
現在 $23.81
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
57
適正価値
センチメント
70
強気
リスク
44
やや高いリスク
モメンタム
71
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
日中レンジ
現在 $23.81
52週レンジ
現在 $23.81
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 6238.4万 USD | 4206.9万 USD | 3652.7万 USD | 2486万 USD | 3704.2万 USD |
| 売上原価 | 228.1万 USD | — | — | — | — |
| 粗利益 | 6010.3万 USD | 4206.9万 USD | 3652.7万 USD | 2486万 USD | 3704.2万 USD |
| 研究開発 | 1.32億 USD | 1.44億 USD | 1.15億 USD | 1.06億 USD | 7763.6万 USD |
| 販売・一般管理 | 4150.8万 USD | 4374.6万 USD | 3550.2万 USD | 3002.5万 USD | 1759.6万 USD |
| 営業費用 | 1.71億 USD | 1.88億 USD | 1.51億 USD | 1.36億 USD | 9523.2万 USD |
| 受取利息 | 563万 USD | 789万 USD | 661.9万 USD | 145.6万 USD | 49.5万 USD |
| 減価償却費と償却費 | 228.1万 USD | 249.9万 USD | 241.5万 USD | 160.8万 USD | 89.7万 USD |
| 営業利益 | −1.11億 USD | −1.46億 USD | −1.14億 USD | −1.11億 USD | −5819万 USD |
| 純利益 | −1.02億 USD | −1.3億 USD | −1.02億 USD | −1.08億 USD | −5823.5万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI1.01億0.00%2.3兆 USD0.03%$381.94+0.63%
State Street SPDR S&P Biotech ETFXBI9298.5万0.94%98.74億 USD0.35%$153.77+3.00%
iShares Russell 2000 ETFIWM8375.15万0.11%787.4億 USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF3284.46万0.03%954億 USD0.05%$235+0.80%
iShares Russell 2000 Growth ETFIWO2936.86万0.21%139.17億 USD0.24%$356.78+0.94%
iShares Biotechnology ETFIBB2437.56万0.23%108.2億 USD0.44%$206.49+3.00%
Vanguard Russell 2000 ETFVTWO1849.03万0.10%180億 USD0.06%$112.66+0.50%
Schwab U.S. Small-Cap ETFSCHA1731.91万0.08%218.24億 USD0.03%$32.79+0.40%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
